Hassan Sefrioui

Prof. Hassane Sefrioui has over 18 years R&D experience in both academia and industrial settings.

Prior to joining MASCIR (Moroccan Foundation For advanced Science Innovation & research), Hassane held Senior R&D management positions at the European biotech industry sector. He was heading osteoarthritis drug discovery program ‘targeted therapeutics’ at Tigenix (Euronext) (Belgium). Before that, he was leading projects in inflammatory diseases and cancer at Biotie Therapeutics (NASDAQ) (former 4AZA Biosciences) (Belgium) and Diatos (France). Hassane holds an M.S degree in Biotechnology from the University of Liège (Belgium), a Ph.D. in Medical Sciences from the University of Leuven, School of Medicine (Belgium) and a Postdoctoral fellowship from the University of California San Diego, School of Medicine (USA). Hassane published 6 patents and over 25 international peerviewed publications (http://www.researchgate.net/profile/Hassan_Sefrioui) in cancer, transplantation, and diagnostics. He is a member of the Editorial board of several journals and has been awarded NIH fellowships from the University of California San Diego (USA) & the University of Minessota Twin Cities (USA). 

Since 2010, Hassane is the Director of Medical Biotechnology Center at MAScIR. Amongst the achievement of his team at MAScIR:

- The development & international validation of the first 2 Moroccan molecular diagnostic kits targeting leukemia & breast cancer

- 3 international patents

- A grant from the Moroccan government to initiate the development of the first Moroccan prototype of a bio-generic Medicine